Developing an effective drug-device combination product for self-administered biologics is a complex process.
It requires critical decisions during delivery system selection. Making the right choices at an early stage can reduce risks throughout your drug development journey. Ultimately, a well-executed strategy will help support integration with manufacturing operations and successful drug delivery.
During this webinar, Becton Dickinson and PCI Pharma Services shared insights on topics including:
- Design space evolution and potential trade-offs when selecting device components for combination products
- Approaches to de-risk your drug delivery system
- Factor to consider when selecting a CDMO for secondary device assembly with biologics
- Insights into how your delivery system and key partners can support successful commercialization of your combination product.